DC Chemicals

全部产品 / DC11512

Acrizanib
CAT. NO. DC11512

Acrizanib

包装与价格

包装规格价格
100 mg¥9,500 CNY询价 →
250 mg¥17,000 CNY询价 →
1 g¥34,000 CNY询价 →

现货。交期、运费及最终报价请向客服确认。

上海仓库现货

数量及交期请咨询客服。

微信扫码询价 · 021-58447131

产品概要

Acrizanib 是一种VEGFR-2抑制剂,对BaF3-KDR的IC50为17.4 nM。

仅供科研使用。研究结果取决于实验条件,不构成产品性能保证。

产品身份与规格

目录号DC11512
产品名称Acrizanib
CAS1229453-99-9
分子式C20H18F3N7O2
分子量445.3978
纯度>98%
SMILESFC(C1=C([H])C(=NN1C([H])([H])[H])N([H])C(N1C([H])=C([H])C2C([H])=C(C([H])=C([H])C1=2)OC1C([H])=C(C([H])([H])N([H])C([H])([H])[H])N=C([H])N=1)=O)(F)F

来源列示的产品规格;具体要求以批次 COA 为准。

原始研究与产品文件

详细实验条件、性能数据和参考文献请参见英文原始资料。COA、SDS及批次文件请向客服索取。

英文原始产品资料

原文参考文献

Rat ocular PK studies with Acrizanib shows a distinctly different profile from that observed with compound 25. While prolonged exposure is once again evident in the PEC, the AUC ratio to the level of Acrizanib in plasma is markedly increased (>21000-fold higher exposure in the PEC than plasma on day 11). Furthermore, unlike 25, Acrizanib also afford much improved retina to plasma AUC exposure ratio after 10 days of dosing (598× for Acrizanib vs 0.8× for 25)[1].

相关科研产品